Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

BAY CLINICAL LABORATORIES

NPI: 1376995910 · ANNAPOLIS, MD 21401 · Clinical Medical Laboratory · NPI assigned 07/07/2016

$9.73M
Total Medicaid Paid
167,881
Total Claims
48,105
Beneficiaries
4
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialPETERSON, CHRISTINA (BILLING MANAGER)
NPI Enumeration Date07/07/2016

Related Entities

Other providers sharing the same authorized official: PETERSON, CHRISTINA

ProviderCityStateTotal Paid
UNIVERSITY PSYCHOLOGICAL CENTER, INC. BALTIMORE MD $3.61M
PROJECT CHESAPEAKE LLC WALDORF MD $1.11M
UNIVERSITY PSYCHOLOGICAL CENTER, INC. BERWYN HEIGHTS MD $193K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 38,137 $2.69M
2019 25,195 $1.51M
2020 20,805 $1.16M
2021 22,288 $1.19M
2022 21,863 $1.14M
2023 20,720 $1.08M
2024 18,873 $966K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 137,954 33,710 $7.03M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 29,258 13,773 $2.63M
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 557 525 $69K
87811 Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) 112 97 $2K